Roger Cady

12.6k total citations · 3 hit papers
215 papers, 8.9k citations indexed

About

Roger Cady is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Roger Cady has authored 215 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Psychiatry and Mental health, 137 papers in Pathology and Forensic Medicine and 91 papers in Physiology. Recurrent topics in Roger Cady's work include Migraine and Headache Studies (205 papers), Trigeminal Neuralgia and Treatments (124 papers) and Sympathectomy and Hyperhidrosis Treatments (84 papers). Roger Cady is often cited by papers focused on Migraine and Headache Studies (205 papers), Trigeminal Neuralgia and Treatments (124 papers) and Sympathectomy and Hyperhidrosis Treatments (84 papers). Roger Cady collaborates with scholars based in United States, Denmark and United Kingdom. Roger Cady's co-authors include Paul L. Durham, Richard B. Lipton, Curtis P. Schreiber, Alice S. Batenhorst, Ryan Cady, David W. Dodick, Joe Hirman, Stewart J. Tepper, Kathleen Farmer and Martha Bayliss and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Roger Cady

208 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A six-item short-form survey for measuring headache impact: The HIT-6™

2003 1.0k citations Roger Cady et al. profile →
Efficacy and safety of eptinezumab in patients with chronic migraine

2020 273 citations Richard B. Lipton, Jeff Smith et al. Neurology profile →
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

2020 264 citations Joel R. Saper, Roger Cady et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger Cady United States	51	7.6k	5.1k	3.5k	950	915	215	8.9k
Stewart J. Tepper United States	47	7.8k 1.0×	4.9k 1.0×	3.0k 0.8×	856 0.9×	852 0.9×	286	9.3k
Julio Pascual Spain	45	6.2k 0.8×	3.8k 0.7×	2.5k 0.7×	1.4k 1.4×	885 1.0×	280	8.2k
Joel R. Saper United States	42	5.4k 0.7×	3.4k 0.7×	2.8k 0.8×	755 0.8×	649 0.7×	119	6.5k
Domenico D’Amico Italy	42	4.8k 0.6×	2.8k 0.6×	1.7k 0.5×	617 0.6×	661 0.7×	250	6.4k
Merle L. Diamond United States	27	5.1k 0.7×	3.1k 0.6×	1.9k 0.5×	346 0.4×	561 0.6×	52	5.6k
Antoinette MaassenVanDenBrink Netherlands	45	4.9k 0.6×	2.6k 0.5×	1.8k 0.5×	376 0.4×	580 0.6×	222	6.9k
Jan Lewis Brandes United States	36	4.4k 0.6×	2.8k 0.5×	1.8k 0.5×	433 0.5×	473 0.5×	73	5.0k
Patricia Pozo‐Rosich Spain	37	4.1k 0.5×	2.3k 0.5×	1.3k 0.4×	1.3k 1.3×	380 0.4×	206	5.2k
Seymour Diamond United States	29	4.5k 0.6×	2.6k 0.5×	1.8k 0.5×	430 0.5×	568 0.6×	160	5.4k
Charly Gaul Germany	40	3.5k 0.5×	2.3k 0.5×	1.6k 0.4×	660 0.7×	423 0.5×	223	5.2k

Countries citing papers authored by Roger Cady

Since Specialization

Citations

This map shows the geographic impact of Roger Cady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Cady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Cady more than expected).

Fields of papers citing papers by Roger Cady

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Cady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Cady. The network helps show where Roger Cady may publish in the future.

Co-authorship network of co-authors of Roger Cady

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Cady. A scholar is included among the top collaborators of Roger Cady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Cady. Roger Cady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lipton, Richard B., Dawn C. Buse, Stephanie J. Nahas, et al.. (2023). Risk factors for migraine disease progression: a narrative review for a patient-centered approach. Journal of Neurology. 270(12). 5692–5710. 47 indexed citations

Starling, Amaal J., Robert P. Cowan, Dawn C. Buse, et al.. (2023). Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized PROMISE ‐2 trial. Headache The Journal of Head and Face Pain. 63(2). 264–274. 9 indexed citations

Starling, Amaal J., et al.. (2023). Treatment with Eptinezumab for Migraine Prevention in People with Chronic Migraine and Medication-Overuse Headache: A Plain Language Summary. Pain Management. 13(6). 317–327. 1 indexed citations

Riskin, Daniel K., et al.. (2023). Using artificial intelligence to identify patients with migraine and associated symptoms and conditions within electronic health records. BMC Medical Informatics and Decision Making. 23(1). 121–121. 10 indexed citations

Cowan, Robert P., Michael J. Marmura, Hans‐Christoph Diener, et al.. (2022). Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. The Journal of Headache and Pain. 23(1). 115–115. 2 indexed citations

Lipton, Richard B., Larry Charleston, Cristina Tassorelli, et al.. (2022). Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials. The Journal of Headache and Pain. 23(1). 23–23. 6 indexed citations

Martin, Vincent T., Marina Janelidze, Joe Hirman, et al.. (2022). Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. Clinical Therapeutics. 44(3). 389–402. 13 indexed citations

Smith, Timothy R., Egilius L.H. Spierings, Roger Cady, et al.. (2021). Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. The Journal of Headache and Pain. 22(1). 16–16. 34 indexed citations

Dodick, David W., Timothy R. Smith, Roger Cady, et al.. (2019). Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials (S17.004). Neurology. 92(15_supplement). 3 indexed citations

10.

Lipton, Richard B., et al.. (2019). PND81 PATIENT GLOBAL IMPRESSION OF CHANGE RELATED TO IMPROVEMENT IN MOST BOTHERSOME SYMPTOM FOLLOWING TREATMENT WITH EPTINEZUMAB. Value in Health. 22. S285–S285. 1 indexed citations

11.

Cady, Roger, et al.. (2017). Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The Journal of Headache and Pain. 18(1). 17–17. 26 indexed citations

12.

Cady, Roger, et al.. (2015). Long‐Term Efficacy of a Double‐Blind, Placebo‐Controlled, Randomized Study for Repetitive Sphenopalatine Blockade With Bupivacaine vs Saline With the Tx 360 ^® Device for Treatment of Chronic Migraine. Headache The Journal of Head and Face Pain. 55(4). 529–542. 40 indexed citations

13.

Cady, Roger, et al.. (2013). An Exploratory Study of Salivary Calcitonin Gene‐Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With Onabotulinumtoxin A in Chronic Migraine. Headache The Journal of Head and Face Pain. 54(2). 269–277. 48 indexed citations

14.

Hu, Xiaohan, Wendy L. Golden, S. Bolge, et al.. (2010). Predictability of Future Attacks by Migraineurs: A Prospective Observational Study. Headache The Journal of Head and Face Pain. 50(8). 1296–1305. 11 indexed citations

15.

Cady, Roger, Frederick G. Freitag, Ninan T. Mathew, et al.. (2009). Allodynia‐Associated Symptoms, Pain Intensity and Time to Treatment: Predicting Treatment Response in Acute Migraine Intervention. Headache The Journal of Head and Face Pain. 49(3). 350–363. 23 indexed citations

16.

Apostol, George, Roger Cady, Genevieve Laforet, et al.. (2008). Divalproex Extended‐Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double‐Blind, Placebo‐Controlled Study. Headache The Journal of Head and Face Pain. 48(7). 1012–1025. 43 indexed citations

17.

Newman, Lawrence C., et al.. (2008). Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. International Journal of Clinical Practice. 62(12). 1889–1899. 9 indexed citations

18.

Cady, Roger. (2007). The Convergence Hypothesis. Headache The Journal of Head and Face Pain. 47(s1). S44–51. 38 indexed citations

19.

Wenzel, Richard, Marcus J. Dortch, Roger Cady, Jennifer H. Lofland, & Seymour Diamond. (2004). Migraine Headache Misconceptions: Barriers to Effective Care. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(5). 638–648. 17 indexed citations

20.

Cady, Roger & David W. Dodick. (2002). Diagnosis and Treatment of Migraine. Mayo Clinic Proceedings. 77(3). 255–261. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact